Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Claritas Genomics | RCV000170413 | SCV000222842 | uncertain significance | Heterotopia, periventricular, X-linked dominant | 2014-10-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000640771 | SCV000250390 | likely benign | not provided | 2020-07-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001442515 | SCV001645464 | likely benign | Heterotopia, periventricular, X-linked dominant; Melnick-Needles syndrome; Oto-palato-digital syndrome, type II; Frontometaphyseal dysplasia | 2024-12-12 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002321679 | SCV002631348 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2019-07-08 | criteria provided, single submitter | clinical testing | The p.D1354N variant (also known as c.4060G>A), located in coding exon 23 of the FLNA gene, results from a G to A substitution at nucleotide position 4060. The aspartic acid at codon 1354 is replaced by asparagine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species; however, asparagineis the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV000640771 | SCV004225701 | uncertain significance | not provided | 2022-11-23 | criteria provided, single submitter | clinical testing | PP2 |